Korea pharma market access: Inside the 2026 drug pricing policy reforms

Three domestic reforms are pushing Korea from the back of the launch queue to the front. 

For global pharmaceutical companies, South Korea has long been a paradox: clinically sophisticated, fast-growing, and yet often deprioritized in global launch sequencing. 

Three structural barriers drove this dynamic. First, reimbursement timelines were exceptionally long. Second, conservative cost-effectiveness requirements resulted in low reimbursement prices that discouraged commercialization of high-cost therapies. Third, those relatively low prices were publicly disclosed, creating potential exposure through international reference pricing (IRP) systems in other markets. Together, these barriers often led manufacturers to delay launches in Korea despite the market’s underlying attractiveness. 

That dynamic is now beginning to change. A sweeping reform package announced by Korea’s Ministry of Health and Welfare (MoHW) directly targets all…